Study identifies a common genetic risk factor for colorectal and prostate cancer

July 08, 2007

A study led by researchers at the Keck School of Medicine of the University of Southern California (USC) has found that one of seven genetic risk factors previously identified as increasing the probability of developing prostate cancer also increases the probability of developing colorectal cancer. As in the previous prostate cancer study, which was also conducted by USC researchers and published in the April 2007 edition of Nature Genetics, the colorectal cancer risk factor is located in a region of the human genome devoid of known genes on chromosome 8. The study's complete findings will be published in the July 8 online edition of Nature Genetics.

"This is an important finding because, for the first time, a common genetic risk factor for multiple cancers has been identified," says lead author Christopher Haiman, assistant professor of preventive medicine at the Keck School of Medicine of USC. Adding, "There appears to be something fundamental occurring in this region that influences not only colorectal and prostate cancer, but perhaps cancers in general." (Another recently published study, in which USC researchers also were involved, identified variants in this same chromosomal region as playing a predictive role relative to the risk of developing breast cancer.)

For the current colorectal cancer study, the USC team genotyped six of the seven variants previously identified as increasing the risk of prostate cancer development. The samples analyzed totaled 1,807 invasive colorectal cancer cases and 5,511 controls. These samples were drawn from five populations (African Americans, Japanese Americans, Native Hawaiians, Latinos, and European Americans) included in the Multiethnic Cohort Study, an epidemiological study of more than 215,000 people from Los Angeles and Hawaii created in 1993 by Brian Henderson, dean, Keck School of Medicine of USC, and Laurence Kolonel of the University of Hawaii.

According to Henderson, co-author of the colorectal cancer study, "Having previously identified several genetic risk factors related to prostate cancer, and now having identified one of these same variants as predictive of colorectal cancer risk, brings us closer to our long-term goal of developing a model that more precisely pinpoints who is at greater risk for developing colorectal, prostate, and other cancers." However, Henderson notes, "We still need to identify the biological mechanism through which these variants are influencing the development of various cancers."
-end-
The study also involved researchers at the University of Hawaii.

The National Institutes of Health and the National Cancer Institute provided funding for this study.

University of Southern California

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.